Effects of once-daily versus twice-daily darunavir/ritonavir on lipid parameters at week 48 in treatment-experienced, HIV-1-infected patients with no darunavir resistance-associated mutations (RAMs) in the ODIN study

被引：0
|
作者：
Arribas, J. [1 ]
Arathoon, E. [2 ]
Gonsalez, C. R. [3 ]
Latiff, G. H. [4 ]
Van De Casteele, T. [5 ]
De Doncker, P. [5 ]
De La Rosa, G. [6 ]
Spinosa-Guzman, S. [5 ]
机构：
[1] Hosp Univ La Paz, IdiPAZ, Madrid, Spain
[2] Clin Familiar Luis Angel Garcia, Guatemala City, Guatemala
[3] Univ Sao Paulo, Hosp Clin, Fac Med, Pinheiros, Brazil
[4] Maxwell Ctr, Durban, South Africa
[5] Tibotec BVBA, Beerse, Belgium
[6] Tibotec Therapeut, Titusville, NJ USA
来源：
ANTIVIRAL THERAPY | 2010年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A59 / A60
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily
    Autar, RS
    Ananworanich, J
    Apateerapong, W
    Sankote, J
    Hill, A
    Hirschel, B
    Cooper, D
    Lange, J
    Phanuphak, P
    Ruxrungtham, K
    Burger, D
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (04) : 785 - 790
  • [32] Treatment of advanced HIV disease in antiretroviral-naive HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine
    Uy, Jonathan
    Yang, Rong
    Wirtz, Victoria
    Sheppard, Louise
    Farajallah, Awny
    McGrath, Donnie
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2011, 23 (11): : 1500 - 1504
  • [33] Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients
    Jablonowska, Elzbieta
    Siwak, Ewa
    Bociaga-Jasik, Monika
    Gasiorowski, Jacek
    Kalinowska, Anna
    Burkacka, Ewa Firlag
    Wojcik-Cichy, Kamila
    Piatek, Anna
    Cielniak, Iwona
    Horban, Andrzej
    PLOS ONE, 2019, 14 (01):
  • [34] Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study
    Molina, Jean-Michel
    Andrade-Villanueva, Jaime
    Echevarria, Juan
    Chetchotisakd, Ploenchan
    Corral, Jorge
    David, Neal
    Moyle, Graeme
    Mancini, Marco
    Percival, Lisa
    Yang, Rong
    Wirtz, Victoria
    Lataillade, Max
    Absalon, Judith
    McGrath, Donnie
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (03) : 323 - 332
  • [35] ARTEMIS: 192-WEEK EFFICACY AND SAFETY OF ONCE DAILY DARUNAVIR/RITONAVIR (DRV/R) VERSUS LOPINAVIR/R (LPV/R) IN TREATMENT-NAIVE HIV-1-INFECTED ADULTS
    Lazzarin, A.
    Orkin, C.
    De Jesus, E.
    Khanlou, H.
    Stoehr, A.
    Supparatpinyo, K.
    Van de Casteele, T.
    Lathouwers, E.
    Garau, M.
    INFECTION, 2011, 39 : S26 - S27
  • [36] Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial
    Overton, Edgar Turner
    Tebas, Pablo
    Coate, Bruce
    Ryan, Robert
    Perniciaro, Amy
    Dayaram, Yaswant K.
    De la Rosa, Guy
    Baugh, Bryan P.
    HIV CLINICAL TRIALS, 2016, 17 (02): : 72 - 77
  • [37] Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)
    Viciana, Pompeyo
    Rubio, Rafael
    Ribera, Esteve
    Knobel, Hernando
    Iribarren, Jose A.
    Arribas, Jose R.
    Perez-Molina, Jose A.
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2008, 26 (03): : 127 - 134
  • [38] Comparable virological outcomes, patterns, and prevalence of emergent resistance in treatment-experienced (TE) HIV-1-infected patients receiving a boosted protease inhibitor (bPI) with maraviroc once daily (QD) or twice daily (BID)
    Craig, C.
    Lewis, M.
    Simpson, P.
    Burnside, R.
    Valdez, H.
    Heera, J.
    Westby, M.
    ANTIVIRAL THERAPY, 2011, 16 : A72 - A72
  • [39] Efficacy and safety results from a randomized, double blind, active controlled trial of elvitegravir (once-daily) versus raltegravir (twice-daily) in treatment-experienced HIV-positive patients: long term 96-week data
    Elion, R.
    Molina, J-M.
    Arribas-Lopez, J-R.
    Cooper, D.
    Maggiolo, F.
    Wilkins, E.
    Conway, B.
    Liu, Y-P.
    Zhong, L.
    Margot, N.
    Szwarcberg, J.
    Rhee, M.
    Cheng, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 54 - 55
  • [40] Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients
    Gathe, Joseph
    Andrade-Villanueva, Jaime
    Santiago, Steven
    Horban, Andrzej
    Nelson, Mark
    Cahn, Pedro
    Bogner, Johannes
    Spencer, David
    Podzamczer, Daniel
    Yong, Chan-Loi
    Thuy Nguyen
    Zhang, Wei
    Drulak, Murray
    Quinson, Anne-Marie
    ANTIVIRAL THERAPY, 2011, 16 (05) : 759 - 769
12345